SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

Are you looking for effective medications to treat 'SGLT2 Inhibitors: An Evolution in Diabetes Mellitus?'? This page serves as your comprehensive resource hub, featuring the latest medications ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...

[83] List et al. (2009) T2DM drug-naive patients ... Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis.

Monotherapy with SGLT2 inhibitors or GLP-1RAs is associated with ... Please see the original reference for a full list of authors’ disclosures.